Who Paid My Doc
Kimberly Workowski
Infectious Disease Atlanta, GA Medical Doctor
NPI 1588676712 CMS profile 298384
550 Peachtree St Ne, 7Th Floor, Atlanta, GA 30308
General payments
$53,059
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$1,971,498
Through program year 2025, Kimberly Workowski of Atlanta, GA is reported in the CMS Open Payments database as having received $53,059 across 53 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,971,498 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Infectious Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,350 | 3 | |
| 2024 | General | $15,269 | 8 | |
| 2023 | General | $6,699 | 16 | |
| 2022 | General | $6,319 | 5 | |
| 2021 | General | $12,495 | 5 | |
| 2020 | General | $2,670 | 2 | |
| 2019 | General | $8,256 | 14 |
Beside peers
- Kimberly Workowski
- Infectious Disease median
- Middle half of Infectious Disease
- National median
In program year 2025, general payments to Kimberly Workowski were reported at $1,350. Among 3,905 Infectious Disease profiles paid that year, the median was $188 and the middle half received between $57 and $766.
Show as a table
| Year | Kimberly Workowski | Infectious Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $8,256 | $190 | $60–$862 | $163 |
| 2020 | $2,670 | $124 | $32–$606 | $114 |
| 2021 | $12,495 | $148 | $38–$905 | $132 |
| 2022 | $6,319 | $166 | $50–$834 | $149 |
| 2023 | $6,699 | $171 | $57–$787 | $160 |
| 2024 | $15,269 | $176 | $52–$752 | $164 |
| 2025 | $1,350 | $188 | $57–$766 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 88 drugsPart D claims
3,922
Drug cost
$3,672,370
Branded share of claims
44.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 377 | $1,478,300 | |
| Tivicay Dolutegravir Sodium | Brand | 217 | $489,547 | |
| Triumeq Abacavir/Dolutegravir/Lamivudi | Brand | 100 | $375,643 | |
| Descovy Emtricitabine/Tenofov Alafenam | Brand | 123 | $269,007 | |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | Brand | 56 | $226,834 | |
| Prezcobix Darunavir/Cobicistat | Brand | 83 | $193,081 | |
| Stribild Elviteg/Cob/Emtri/Tenofo Disop | Brand | 36 | $133,039 | |
| Isentress Raltegravir Potassium | Brand | 48 | $87,474 | |
| Complera Emtricita/Rilpivirine/Tenof Df | Brand | 25 | $75,181 | |
| Prezista Darunavir | Brand | 35 | $69,722 |
The 10 drugs with the highest cost, of 88 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,546 Part D prescribers listed as Infectious Disease; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 18 billing codesPaid by Medicare
$13,843
Medicare patients
66
Services billed
182
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Chronic kidney disease | 58% | |
| Diabetes | 48% | |
| Arthritis | 45% | |
| Heart failure | 41% | |
| Depression | 36% | |
| Ischemic heart disease | 29% | |
| COPD | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
53 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Infectious Disease in Georgia
Related records
Infectious Disease in Georgia
Practitioners in the same specialty and state, ranked by reported value.
All Infectious Disease
Everyone recorded under this specialty, nationwide.
Doctors in Georgia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.